{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:03:07Z","timestamp":1789398187902,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":77,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Inflammatory bowel disease (IBD) has been frequently reported in patients with primary immunodeficiency; however, the frequency and pattern of immunological abnormalities among adult patients with established IBD remain insufficiently characterized. We aimed to systematically evaluate immunological parameters in adult patients with established IBD. Additionally, we sought to identify clinical factors associated with laboratory-defined immunological deviations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective observational cohort study, we analyzed 108 adults with Crohn\u2019s disease or ulcerative colitis who underwent structured immunological evaluation as part of routine clinical care between 2011 and 2015 (a period of standardized screening). We excluded patients with major causes of secondary immunodeficiency (e.g., advanced renal failure, HIV infection, severe malnutrition). However, we recorded exposure to medications that could potentially cause secondary immunosuppression. The predefined laboratory panel included serum immunoglobulins, vaccine antibody responses, isohemagglutinin titers (not assessed in blood group AB), peripheral lymphocyte subsets (reported as percentages), and neutrophil phagocytic function, interpreted using standardized reference ranges. Immunological findings were categorized according to the IUIS 2025 phenotypic framework. Multivariable logistic regression was performed to assess factors associated with laboratory-defined immunological deviations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Clinically significant immunological disorders were identified in 12 patients (11.1%), and laboratory-defined (defined as combined defects across immune compartments) immunological deviations in 60 patients (55.6%). Reduced CD19\u207a B-cell percentages were observed in 45 patients (42.1%) and decreased NK cell percentages in 17 patients (15.9%). In multivariable analysis, increasing age (OR 1.064 per year; 95% CI 1.029\u20131.100;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and male sex (OR 3.61; 95% CI 1.32\u20139.87;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.012) were independently associated with laboratory-defined immunological deviations; medication exposure showed a borderline association (OR 2.78; 95% CI 0.99\u20137.76;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.052).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this adult IBD cohort evaluated using a structured laboratory framework, measurable immune alterations were common, although most did not meet criteria for clinically significant immunological disorders. These findings highlight immune heterogeneity in adult IBD and support further prospective studies with longitudinal outcomes to clarify the clinical implications and to define which patient subgroups may benefit from targeted immunological assessment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-026-05072-1","type":"journal-article","created":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T23:14:52Z","timestamp":1782688492000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Systematic immunological evaluation in adult patients with inflammatory bowel disease"],"prefix":"10.1186","volume":"26","author":[{"given":"Ali Can","family":"Erdem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huseyin","family":"Ataseven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"As\u0131l","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevket","family":"Arslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramazan","family":"Ucar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadan","family":"Soyyigit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramazan","family":"Dertli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"issue":"2","key":"5072_CR1","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.3390\/ijms24021526","volume":"24","author":"A Saez","year":"2023","unstructured":"Saez A, Herrero-Fernandez B, Gomez-Bris R, S\u00e1nchez-Martinez H, Gonzalez-Granado JM. Pathophysiology of Inflammatory Bowel Disease: Innate Immune System. Int J Mol Sci. 2023;24(2):1526. https:\/\/doi.org\/10.3390\/ijms24021526.","journal-title":"Int J Mol Sci"},{"issue":"17","key":"5072_CR2","doi-asserted-by":"publisher","first-page":"6237","DOI":"10.3390\/jcm14176237","volume":"14","author":"I Silva","year":"2025","unstructured":"Silva I, Da Silva MTB. Inflammatory Bowel Disease (IBD): Clinical Diagnosis and Treatment. J Clin Med. 2025;14(17):6237. https:\/\/doi.org\/10.3390\/jcm14176237.","journal-title":"J Clin Med"},{"key":"5072_CR3","doi-asserted-by":"publisher","unstructured":"Dolu S. Pathogenesis of Inflammatory Bowel Disease. J Enterocolitis. Published online 2025. https:\/\/doi.org\/10.14744\/Jenterocolitis.2025.15570","DOI":"10.14744\/Jenterocolitis.2025.15570"},{"issue":"7","key":"5072_CR4","doi-asserted-by":"publisher","first-page":"5534","DOI":"10.3390\/cimb45070350","volume":"45","author":"A Padoan","year":"2023","unstructured":"Padoan A, Musso G, Contran N, Basso D, Inflammation. Autoinflammation and Autoimmunity in Inflammatory Bowel Diseases. Curr Issues Mol Biol. 2023;45(7):5534\u201357. https:\/\/doi.org\/10.3390\/cimb45070350.","journal-title":"Curr Issues Mol Biol"},{"key":"5072_CR5","doi-asserted-by":"publisher","unstructured":"Hu C, Liao S, Lv L, Li C, Mei Z. Intestinal Immune Imbalance is an Alarm in the Development of IBD. Subramanian VS, ed. Mediators Inflamm. 2023;2023:1\u201317. https:\/\/doi.org\/10.1155\/2023\/1073984","DOI":"10.1155\/2023\/1073984"},{"key":"5072_CR6","doi-asserted-by":"publisher","unstructured":"Hosseini A, Sayyari A, Mohammadzadeh S, et al. Gastrointestinal Manifestations in Children with Immunodeficiency Referred to a Tertiary Hospital. Shiraz E-Med J. 2025;26(4). https:\/\/doi.org\/10.5812\/semj-157393.","DOI":"10.5812\/semj-157393"},{"key":"5072_CR7","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.3389\/fimmu.2019.01272","volume":"10","author":"SM El-Helou","year":"2019","unstructured":"El-Helou SM, Biegner AK, Bode S, et al. The German National Registry of Primary Immunodeficiencies (2012\u20132017). Front Immunol. 2019;10:1272. https:\/\/doi.org\/10.3389\/fimmu.2019.01272.","journal-title":"Front Immunol"},{"issue":"5","key":"5072_CR8","doi-asserted-by":"publisher","first-page":"976","DOI":"10.5114\/ada.2022.120887","volume":"39","author":"E \u00d6zdemir","year":"2022","unstructured":"\u00d6zdemir E. Retrospective evaluation of adults with primaryimmunodeficiency disease. Adv Dermatol Allergol. 2022;39(5):976\u20139. https:\/\/doi.org\/10.5114\/ada.2022.120887.","journal-title":"Adv Dermatol Allergol"},{"issue":"2","key":"5072_CR9","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3390\/jcm14020497","volume":"14","author":"L Velthof","year":"2025","unstructured":"Velthof L, Geldof J, Truyens M, et al. Gastrointestinal Disease in Common Variable Immunodeficiency Disorder (CVID): Histological Patterns, Diagnostic Clues and Pitfalls for the Pathologist and Gastroenterologist. J Clin Med. 2025;14(2):497. https:\/\/doi.org\/10.3390\/jcm14020497.","journal-title":"J Clin Med"},{"issue":"8","key":"5072_CR10","doi-asserted-by":"publisher","first-page":"102872","DOI":"10.1016\/j.autrev.2021.102872","volume":"20","author":"T Both","year":"2021","unstructured":"Both T, Dalm VASH, Richardson SA, et al. Inflammatory bowel disease in primary immunodeficiency disorders is a heterogeneous clinical entity requiring an individualized treatment strategy: A systematic review. Autoimmun Rev. 2021;20(8):102872. https:\/\/doi.org\/10.1016\/j.autrev.2021.102872.","journal-title":"Autoimmun Rev"},{"key":"5072_CR11","doi-asserted-by":"publisher","first-page":"893803","DOI":"10.3389\/fimmu.2022.893803","volume":"13","author":"V Van Unen","year":"2022","unstructured":"Van Unen V, Ouboter LF, Li N, et al. Identification of a Disease-Associated Network of Intestinal Immune Cells in Treatment-Naive Inflammatory Bowel Disease. Front Immunol. 2022;13:893803. https:\/\/doi.org\/10.3389\/fimmu.2022.893803.","journal-title":"Front Immunol"},{"key":"5072_CR12","doi-asserted-by":"publisher","first-page":"175628482513386","DOI":"10.1177\/17562848251338647","volume":"18","author":"I Rodr\u00edguez-Lago","year":"2025","unstructured":"Rodr\u00edguez-Lago I, Marigorta UM, Mateos B, et al. Natural history, immunological and genetic characteristics of preclinical inflammatory bowel disease (EARLY): study protocol for a prospective cohort study. Ther Adv Gastroenterol. 2025;18:17562848251338647. https:\/\/doi.org\/10.1177\/17562848251338647.","journal-title":"Ther Adv Gastroenterol"},{"issue":"1","key":"5072_CR13","doi-asserted-by":"publisher","first-page":"e20250002","DOI":"10.70962\/jhi.20250002","volume":"1","author":"AA Bousfiha","year":"2025","unstructured":"Bousfiha AA, Jeddane L, Moundir A, et al. The 2024 update of IUIS phenotypic classification of human inborn errors of immunity. J Hum Immun. 2025;1(1):e20250002. https:\/\/doi.org\/10.70962\/jhi.20250002.","journal-title":"J Hum Immun"},{"issue":"9","key":"5072_CR14","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1080\/00365521.2024.2374395","volume":"59","author":"T Guler","year":"2024","unstructured":"Guler T, Kulhas Celik I, Ergani AC, Gumus M, Emiroglu HH, Artac H. Gastrointestinal system involvement in patients with primary immunodeficiency: a single center experience. Scand J Gastroenterol. 2024;59(9):1130\u20136. https:\/\/doi.org\/10.1080\/00365521.2024.2374395.","journal-title":"Scand J Gastroenterol"},{"issue":"1","key":"5072_CR15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1053\/j.gastro.2021.04.063","volume":"161","author":"M Agrawal","year":"2021","unstructured":"Agrawal M, Spencer EA, Colombel JF, Ungaro RC. Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User\u2019s Guide for Adult and Pediatric Gastroenterologists. Gastroenterology. 2021;161(1):47\u201365. https:\/\/doi.org\/10.1053\/j.gastro.2021.04.063.","journal-title":"Gastroenterology"},{"issue":"6","key":"5072_CR16","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/s41422-020-0332-7","volume":"30","author":"D Zheng","year":"2020","unstructured":"Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease. Cell Res. 2020;30(6):492\u2013506. https:\/\/doi.org\/10.1038\/s41422-020-0332-7.","journal-title":"Cell Res"},{"issue":"6","key":"5072_CR17","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/j.immuni.2023.04.017","volume":"56","author":"AR Bourgonje","year":"2023","unstructured":"Bourgonje AR, Andreu-S\u00e1nchez S, Vogl T, et al. Phage-display immunoprecipitation sequencing of the antibody epitope repertoire in inflammatory bowel disease reveals distinct antibody signatures. Immunity. 2023;56(6):1393\u2013e14096. https:\/\/doi.org\/10.1016\/j.immuni.2023.04.017.","journal-title":"Immunity"},{"issue":"2","key":"5072_CR18","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/jebm.12626","volume":"17","author":"L Li","year":"2024","unstructured":"Li L, Cheng R, Wu Y, Lin H, Gan H, Zhang H. Diagnosis and management of inflammatory bowel disease. J Evid-Based Med. 2024;17(2):409\u201333. https:\/\/doi.org\/10.1111\/jebm.12626.","journal-title":"J Evid-Based Med"},{"key":"5072_CR19","doi-asserted-by":"publisher","first-page":"1603990","DOI":"10.3389\/phrs.2021.1603990","volume":"42","author":"P Tavakoli","year":"2021","unstructured":"Tavakoli P, Vollmer-Conna U, Hadzi-Pavlovic D, Grimm MC. A Review of Inflammatory Bowel Disease: A Model of Microbial, Immune and Neuropsychological Integration. Public Health Rev. 2021;42:1603990. https:\/\/doi.org\/10.3389\/phrs.2021.1603990.","journal-title":"Public Health Rev"},{"issue":"2","key":"5072_CR20","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3390\/biomedicines13020305","volume":"13","author":"V Calvez","year":"2025","unstructured":"Calvez V, Puca P, Di Vincenzo F, et al. Novel Insights into the Pathogenesis of Inflammatory Bowel Diseases. Biomedicines. 2025;13(2):305. https:\/\/doi.org\/10.3390\/biomedicines13020305.","journal-title":"Biomedicines"},{"issue":"4","key":"5072_CR21","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1093\/ecco-jcc\/jjx160","volume":"12","author":"C Smids","year":"2018","unstructured":"Smids C, Horjus Talabur Horje CS, Drylewicz J, et al. Intestinal T Cell Profiling in Inflammatory Bowel Disease: Linking T Cell Subsets to Disease Activity and Disease Course. J Crohns Colitis. 2018;12(4):465\u201375. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjx160.","journal-title":"J Crohns Colitis"},{"key":"5072_CR22","doi-asserted-by":"publisher","first-page":"18","DOI":"10.21037\/tgh-23-21","volume":"9","author":"ZH Chen","year":"2024","unstructured":"Chen ZH, Tang YY, Sheng SY, et al. Crohn\u2019s disease treatment and memory T-cell subset changes: insights from a case series. Transl Gastroenterol Hepatol. 2024;9:18\u201318. https:\/\/doi.org\/10.21037\/tgh-23-21.","journal-title":"Transl Gastroenterol Hepatol"},{"issue":"2","key":"5072_CR23","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1093\/gastro\/gou082","volume":"3","author":"T Rai","year":"2015","unstructured":"Rai T, Wu X, Shen B. Frequency and risk factors of low immunoglobulin levels in patients with inflammatory bowel disease. Gastroenterol Rep. 2015;3(2):115\u201321. https:\/\/doi.org\/10.1093\/gastro\/gou082.","journal-title":"Gastroenterol Rep"},{"issue":"7","key":"5072_CR24","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1007\/s10875-022-01299-1","volume":"42","author":"S Sanges","year":"2022","unstructured":"Sanges S, Germain N, Vignes S, et al. Protein-losing Enteropathy as a Complication and\/or Differential Diagnosis of Common Variable Immunodeficiency. J Clin Immunol. 2022;42(7):1461\u201372. https:\/\/doi.org\/10.1007\/s10875-022-01299-1.","journal-title":"J Clin Immunol"},{"issue":"2","key":"5072_CR25","doi-asserted-by":"publisher","first-page":"111","DOI":"10.14744\/cpr.2025.73280","volume":"47","author":"S K\u00fc\u00e7\u00e7\u00fckt\u00fcrk","year":"2025","unstructured":"K\u00fc\u00e7\u00e7\u00fckt\u00fcrk S. CD19 Deficiency Leads to Dysregulation of Phosphoinositide 3-Kinase-Protein Kinase B (PI3K\/AKT) and Nuclear Factor Kappa B (NF-\u03baB) Pathways: Implications for B-Cell Maturation and Immune Function. J Clin Pract Res. 2025;47(2):111\u20138. https:\/\/doi.org\/10.14744\/cpr.2025.73280.","journal-title":"J Clin Pract Res"},{"issue":"1","key":"5072_CR26","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1038\/s41598-024-83954-8","volume":"15","author":"DM Cunha","year":"2025","unstructured":"Cunha DM, Hern\u00e1ndez-P\u00e9rez S, Mattila PK. Enhanced antibody responses in CD19-Cre mice. Sci Rep. 2025;15(1):1348. https:\/\/doi.org\/10.1038\/s41598-024-83954-8.","journal-title":"Sci Rep"},{"issue":"8","key":"5072_CR27","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s11882-017-0724-z","volume":"17","author":"JR Kelsen","year":"2017","unstructured":"Kelsen JR, Sullivan KE. Inflammatory Bowel Disease in Primary Immunodeficiencies. Curr Allergy Asthma Rep. 2017;17(8):57. https:\/\/doi.org\/10.1007\/s11882-017-0724-z.","journal-title":"Curr Allergy Asthma Rep"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-05072-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-05072-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-05072-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T14:04:23Z","timestamp":1789394663000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-026-05072-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5072"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-05072-1","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"assertion":[{"value":"7 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the Ethics Committee for Non-Pharmaceutical and Non-Medical Device Clinical Trials of Necmettin Erbakan University Meram Faculty of Medicine on 04 December 2015 (decision number 2015\/376).Not applicable. Because of the purely retrospective design of this study, the requirement to obtain informed consent was formally waived by the Ethics Committee for Non-Pharmaceutical and Non-Medical Device Clinical Trials of Necmettin Erbakan University Meram Faculty of Medicine.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"558"}}